Insmed Incorporated (NASDAQ:INSM) Shares Sold by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. reduced its stake in Insmed Incorporated (NASDAQ:INSM) by 1.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,193 shares of the biopharmaceutical company’s stock after selling 403 shares during the period. Dana Investment Advisors Inc.’s holdings in Insmed were worth $1,463,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vestal Point Capital LP raised its holdings in shares of Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after buying an additional 850,000 shares during the last quarter. TimesSquare Capital Management LLC bought a new stake in Insmed during the third quarter worth approximately $35,322,000. Victory Capital Management Inc. raised its holdings in Insmed by 209.9% during the third quarter. Victory Capital Management Inc. now owns 455,959 shares of the biopharmaceutical company’s stock worth $33,285,000 after purchasing an additional 308,819 shares in the last quarter. Westfield Capital Management Co. LP bought a new stake in Insmed during the third quarter worth approximately $18,377,000. Finally, Eventide Asset Management LLC raised its holdings in Insmed by 34.2% during the third quarter. Eventide Asset Management LLC now owns 906,395 shares of the biopharmaceutical company’s stock worth $66,167,000 after purchasing an additional 231,210 shares in the last quarter.

Insmed Trading Down 0.2 %

NASDAQ INSM opened at $74.89 on Friday. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of -13.40 and a beta of 1.28. The firm’s 50 day moving average price is $75.66 and its two-hundred day moving average price is $73.81.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Equities analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Insiders Place Their Bets

In other news, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the transaction, the chief executive officer now directly owns 384,960 shares in the company, valued at $26,885,606.40. The trade was a 4.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Martina M.D. Flammer sold 3,344 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the transaction, the insider now owns 102,766 shares in the company, valued at approximately $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 550,957 shares of company stock worth $42,859,028. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent analyst reports. Truist Financial boosted their target price on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, February 21st. HC Wainwright reissued a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Friday, February 21st. Stifel Nicolaus dropped their target price on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Guggenheim reissued a “buy” rating and set a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. Finally, Wells Fargo & Company boosted their target price on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat, Insmed presently has an average rating of “Moderate Buy” and a consensus target price of $93.33.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.